Teva Pharmaceutical Industries Limited (TEVA)
Automate Your Wheel Strategy on TEVA
With Tiblio's Option Bot, you can configure your own wheel strategy including TEVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TEVA
- Rev/Share 15.02
- Book/Share 6.8869
- PB 5.263
- Debt/Equity 2.1963
- CurrentRatio 1.0364
- ROIC 0.0741
- MktCap 41572950000.0
- FreeCF/Share 0.9991
- PFCF 36.2134
- PE 29.5609
- Debt/Assets 0.4266
- DivYield 0
- ROE 0.1995
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TEVA | Barclays | -- | Overweight | -- | $35 | Dec. 9, 2025 |
| Initiation | TEVA | Scotiabank | -- | Sector Outperform | -- | $35 | Dec. 5, 2025 |
| Initiation | TEVA | Goldman | -- | Buy | -- | $24 | June 6, 2025 |
| Initiation | TEVA | Truist | -- | Buy | -- | $25 | May 28, 2025 |
| Upgrade | TEVA | JP Morgan | Neutral | Overweight | -- | $23 | May 12, 2025 |
News
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
Teva beats Q4 estimates driven by a Sanofi milestone and strong Austedo growth. The drugmaker also unveils its 2026 outlook.
Read More
Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript
Published: January 28, 2026 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript
Read More
Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook
Published: January 28, 2026 by: Benzinga
Sentiment: Positive
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its fourth-quarter 2025 financial results on Wednesday, with total revenue of $4.71 billion, beating analysts' expectations of $4.37 billion, according to Benzinga Pro.
Read More
Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Teva Pharmaceutical Industries (TEVA) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q4 Earnings
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now?
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals' rare disease growth, led by surging Cortrophin Gel sales, is outpacing Teva's slower sales momentum in this head-to-head stock comparison.
Read More
Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 13, 2026 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.
Read More
Why Investors Are So Optimistic on Teva
Published: January 12, 2026 by: Barrons
Sentiment: Positive
Teva Pharmaceuticals stock jumped Monday after the drugmaker issued upbeat guidance and targets for the years ahead.
Read More
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Top 2 Health Care Stocks That May Crash In Q1
Published: January 02, 2026 by: Benzinga
Sentiment: Negative
As of Jan. 2, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Read More
S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
Published: December 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva's long-term issuer credit rating to ‘BB+' from ‘BB', with a stable outlook, and that Moody's Ratings Agency ("Moody's") affirmed Teva's B1a rating and revised Teva's outlook to positive from stable. These upgrades mark another significant milestone in Teva's journey toward achieving investment-grade status.
Read More
Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Published: December 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Teva, the Israeli pharmaceutical giant, is reaching new heights, breaking the $30 mark. The rise in its share price reflects both the strengthening of its balance sheet and the rising sales of Austedo and Ajovy. So, sales of Ajovy totaled $169 million in Q3, up 22.5% year-on-year.
Read More
Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks
Published: December 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
Stanley Druckenmiller is a Wall Street legend whose trades are truly worth tracking due to how consistently he has been winning.
Read More
TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia
Published: December 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Teva files an NDA seeking FDA approval for its once-monthly olanzapine LAI for the treatment of adults with schizophrenia.
Read More
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play
Published: December 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.
Read More
3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.
Read More
Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He's Buying Now.
Published: November 24, 2025 by: 24/7 Wall Street
Sentiment: Positive
Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing.
Read More
Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceutical Industries Limited ( TEVA ) UBS Global Healthcare Conference 2025 November 10, 2025 8:45 AM EST Company Participants Richard Francis - President, CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.
Read More
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Brainsway Ltd.
Read More
TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.
Read More
Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working
Published: November 05, 2025 by: CNBC Television
Sentiment: Positive
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's driving growth, and much more.
Read More
Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 Earnings
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Teva Pharmaceuticals stock surges 12% as branded drug sales outperform
Published: November 05, 2025 by: Invezz
Sentiment: Positive
Teva Pharmaceutical Industries Ltd. stock rose 12% after the company reported stronger-than-expected third-quarter results, buoyed by robust growth in its branded drug portfolio.
Read More
About Teva Pharmaceutical Industries Limited (TEVA)
- IPO Date 1982-02-16
- Website https://www.tevapharm.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Richard D. Francis
- Employees 37000